Search Results - "Bristi Basu"

CXCR4 inhibition in human pancreatic and colorectal cancers induces an integrated immune response by Biasci, Daniele, Smoragiewicz, Martin, Connell, Claire M., Wang, Zhikai, Gao, Ya, Thaventhiran, James E. D., Basu, Bristi, Magiera, Lukasz, Johnson, T. Isaac, Bax, Lisa, Gopinathan, Aarthi, Isherwood, Christopher, Gallagher, Ferdia A., Pawula, Maria, Hudecova, Irena, Gale, Davina, Rosenfeld, Nitzan, Barmpounakis, Petros, Popa, Elizabeta Cristina, Brais, Rebecca, Godfrey, Edmund, Mirk, Fraz, Richards, Frances M., Fearon, Douglas T., Janowitz, Tobias, Jodrell, Duncan I.

“…Inhibition of the chemokine receptor CXCR4 in combination with blockade of the PD-1/PD-L1 T cell checkpoint induces T cell infiltration and anticancer…”
Get full text

Phase I clinical trial repurposing all-trans retinoic acid as a stromal targeting agent for pancreatic cancer by Kocher, Hemant M., Basu, Bristi, Froeling, Fieke E. M., Sarker, Debashis, Slater, Sarah, Carlin, Dominic, deSouza, Nandita M., De Paepe, Katja N., Goulart, Michelle R., Hughes, Christine, Imrali, Ahmet, Roberts, Rhiannon, Pawula, Maria, Houghton, Richard, Lawrence, Cheryl, Yogeswaran, Yathushan, Mousa, Kelly, Coetzee, Carike, Sasieni, Peter, Prendergast, Aaron, Propper, David J.

“…Pre-clinical models have shown that targeting pancreatic stellate cells with all-trans-retinoic-acid (ATRA) reprograms pancreatic stroma to suppress pancreatic…”
Get full text

Circulating DNA as prognostic biomarker in patients with advanced hepatocellular carcinoma: a translational exploratory study from the SORAMIC trial by Alunni-Fabbroni, Marianna, Rönsch, Kerstin, Huber, Thomas, Cyran, Clemens C, Seidensticker, Max, Mayerle, Julia, Pech, Maciej, Basu, Bristi, Verslype, Chris, Benckert, Julia, Malfertheiner, Peter, Ricke, Jens

“…Liquid biopsy based on cell-free DNA circulating in plasma has shown solid results as a non-invasive biomarker. In the present study we evaluated the utility…”
Get full text

First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014 by Basu, Bristi, Dean, Emma, Puglisi, Martina, Greystoke, Alastair, Ong, Michael, Burke, Wendy, Cavallin, Maria, Bigley, Graham, Womack, Christopher, Harrington, Elizabeth A, Green, Stephen, Oelmann, Elisabeth, de Bono, Johann S, Ranson, Malcolm, Banerji, Udai

“…AZD2014 is a novel, oral, m-TORC 1/2 inhibitor that has shown in vitro and in vivo efficacy across a range of preclinical human cancer models. A rolling…”
Get full text

Clonal somatic copy number altered driver events inform drug sensitivity in high-grade serous ovarian cancer by Martins, Filipe Correia, Couturier, Dominique-Laurent, de Santiago, Ines, Sauer, Carolin Margarethe, Vias, Maria, Angelova, Mihaela, Sanders, Deborah, Piskorz, Anna, Hall, James, Hosking, Karen, Amirthanayagam, Anumithra, Cosulich, Sabina, Carnevalli, Larissa, Davies, Barry, Watkins, Thomas B. K., Funingana, Ionut G., Bolton, Helen, Haldar, Krishnayan, Latimer, John, Baldwin, Peter, Crawford, Robin, Eldridge, Matthew, Basu, Bristi, Jimenez-Linan, Mercedes, Mcpherson, Andrew W., McGranahan, Nicholas, Litchfield, Kevin, Shah, Sohrab P., McNeish, Iain, Caldas, Carlos, Evan, Gerard, Swanton, Charles, Brenton, James D.

“…Chromosomal instability is a major challenge to patient stratification and targeted drug development for high-grade serous ovarian carcinoma (HGSOC). Here we…”
Get full text

Safety and anti-tumour activity of the IgE antibody MOv18 in patients with advanced solid tumours expressing folate receptor-alpha: a phase I trial by Spicer, James, Basu, Bristi, Montes, Ana, Banerji, Udai, Kristeleit, Rebecca, Miller, Rowan, Veal, Gareth J., Corrigan, Christopher J., Till, Stephen J., Figini, Mariangela, Canevari, Silvana, Barton, Claire, Jones, Paul, Mellor, Sarah, Carroll, Simon, Selkirk, Chris, Nintos, George, Kwatra, Vineet, Funingana, Ionut-Gabriel, Doherty, Gary, Gould, Hannah J., Pellizzari, Giulia, Nakamura, Mano, Ilieva, Kristina M., Khiabany, Atousa, Stavraka, Chara, Chauhan, Jitesh, Gillett, Cheryl, Pinder, Sarah, Bax, Heather J., Josephs, Debra H., Karagiannis, Sophia N.

“…All antibodies approved for cancer therapy are monoclonal IgGs but the biology of IgE, supported by comparative preclinical data, offers the potential for…”
Get full text

Systemic therapy for neuroendocrine tumours of gastroenteropancreatic origin by Basu, Bristi, Sirohi, Bhawna, Corrie, Pippa

“…Systemic therapy is one of a number of treatment options routinely used in the management of advanced, unresectable neuroendocrine tumours (NETs). In contrast…”
Get full text

Baseline Interleukin-6 and -8 predict response and survival in patients with advanced hepatocellular carcinoma treated with sorafenib monotherapy: an exploratory post hoc analysis of the SORAMIC trial by Öcal, Osman, Schütte, Kerstin, Kupčinskas, Juozas, Morkunas, Egidijus, Jurkeviciute, Gabija, de Toni, Enrico N., Ben Khaled, Najib, Berg, Thomas, Malfertheiner, Peter, Klümpen, Heinz Josef, Sengel, Christian, Basu, Bristi, Valle, Juan W., Benckert, Julia, Gasbarrini, Antonio, Palmer, Daniel, Seidensticker, Ricarda, Wildgruber, Moritz, Sangro, Bruno, Pech, Maciej, Ricke, Jens, Seidensticker, Max

“…Purpose To explore the potential correlation between baseline interleukin (IL) values and overall survival or objective response in patients with…”
Get full text

Update on the Genetics of and Systemic Therapy Options for Combined Hepatocellular Cholangiocarcinoma by Azizi, Alexander A., Hadjinicolaou, Andreas V., Goncalves, Carla, Duckworth, Adam, Basu, Bristi

“…Combined hepatocellular-cholangiocarcinoma (cHCC-ICC) is an uncommon and aggressive form of primary liver cancer. Currently, there are no international…”
Get full text

Corrigendum: Sorafenib increases cytochrome P450 lipid metabolites in patient with hepatocellular carcinoma by Leineweber, Can G, Rabehl, Miriam, Pietzner, Anne, Rohwer, Nadine, Rothe, Michael, Pech, Maciej, Sangro, Bruno, Sharma, Rohini, Verslype, Chris, Basu, Bristi, Sengel, Christian, Ricke, Jens, Schebb, Nils Helge, Weylandt, Karsten-H, Benckert, Julia

“…[This corrects the article DOI: 10.3389/fphar.2023.1124214.]…”
Get full text

Sorafenib increases cytochrome P450 lipid metabolites in patient with hepatocellular carcinoma by Leineweber, Can G, Rabehl, Miriam, Pietzner, Anne, Rohwer, Nadine, Rothe, Michael, Pech, Maciej, Sangro, Bruno, Sharma, Rohini, Verslype, Chris, Basu, Bristi, Sengel, Christian, Ricke, Jens, Schebb, Nils Helge, Weylandt, Karsten-H, Benckert, Julia

“…Hepatocellular carcinoma (HCC) is a leading cause of cancer death, and medical treatment options are limited. The multikinase inhibitor sorafenib was the first…”
Get full text

Imaging Glioblastoma Metabolism by Using Hyperpolarized [1- 13 C]Pyruvate Demonstrates Heterogeneity in Lactate Labeling: A Proof of Principle Study by Zaccagna, Fulvio, McLean, Mary A, Grist, James T, Kaggie, Joshua, Mair, Richard, Riemer, Frank, Woitek, Ramona, Gill, Andrew B, Deen, Surrin, Daniels, Charlie J, Ursprung, Stephan, Schulte, Rolf F, Allinson, Kieren, Chhabra, Anita, Laurent, Marie-Christine, Locke, Matthew, Frary, Amy, Hilborne, Sarah, Patterson, Ilse, Carmo, Bruno D, Slough, Rhys, Wilkinson, Ian, Basu, Bristi, Wason, James, Gillard, Jonathan H, Matys, Tomasz, Watts, Colin, Price, Stephen J, Santarius, Thomas, Graves, Martin J, Jefferies, Sarah, Brindle, Kevin M, Gallagher, Ferdia A

“…Purpose To evaluate glioblastoma (GBM) metabolism by using hyperpolarized carbon 13 ( C) MRI to monitor the exchange of the hyperpolarized C label between…”
Get full text

The role of angiogenesis inhibitors in the management of melanoma by Zaki, Kamarul Ahmad, Basu, Bristi, Corrie, Pippa

“…Metastatic melanoma has a very poor prognosis and systemic therapies - both cytotoxic and biological - have not improved outcome in this disease so far. For…”
Get more information

Detection limit of 89Zr-labeled T cells for cellular tracking: an in vitro imaging approach using clinical PET/CT and PET/MRI by Lechermann, Laura M., Manavaki, Roido, Attili, Bala, Lau, Doreen, Jarvis, Lorna B., Fryer, Tim D., Bird, Nick, Aloj, Luigi, Patel, Neel, Basu, Bristi, Cleveland, Matthew, Aigbirhio, Franklin I., Jones, Joanne L., Gallagher, Ferdia A.

“…Purpose Tracking cells in vivo using imaging can provide non-invasive information to understand the pharmacology, efficacy, and safety of novel cell therapies…”
Get full text

An investigator-initiated phase I study of ONX-0801, a first-in-class alpha folate receptor targeted, small molecule thymidylate synthase inhibitor in solid tumors by Banerji, Udai, Ingles Garces, Alvaro Henrique, Michalarea, Vasiliki, Ruddle, Ruth, Raynaud, Florence I., Riisnaes, Ruth, Nava Rodrigues, Daniel, Tunariu, Nina, Porter, Joanna C, Ward, Sarah Emily, Parmar, Mona, Turner, Alison Joanne, Seeramreddi, Satyanarayana, Hall, Emma, Dean, Emma Jane, Basu, Bristi, George, Angela, Kaye, Stan B, Banerjee, Susana N., De Bono, Johann S.

“…Abstract only 2503 Background: ONX-0801 is a first-in-class alpha folate receptor (AFR) targeted thymidylate synthase inhibitor, engineered to differentially…”
Get full text

Hyperpolarized 13C MRI of Tumor Metabolism Demonstrates Early Metabolic Response to Neoadjuvant Chemotherapy in Breast Cancer by Woitek, Ramona, McLean, Mary A, Gill, Andrew B, Grist, James T, Provenzano, Elena, Patterson, Andrew J, Ursprung, Stephan, Torheim, Turid, Zaccagna, Fulvio, Locke, Matthew, Laurent, Marie-Christine, Hilborne, Sarah, Frary, Amy, Beer, Lucian, Rundo, Leonardo, Patterson, Ilse, Slough, Rhys, Kane, Justine, Biggs, Heather, Harrison, Emma, Lanz, Titus, Basu, Bristi, Baird, Richard, Sala, Evis, Graves, Martin J, Gilbert, Fiona J, Abraham, Jean E, Caldas, Carlos, Brindle, Kevin M, Gallagher, Ferdia A

“…PurposeTo compare hyperpolarized carbon 13 (13C) MRI with dynamic contrast material-enhanced (DCE) MRI in the detection of early treatment response in breast…”
Get full text

Clinical trials for pancreatic cancer by Propper, David, Basu, Bristi

Get full text

Quantifying normal human brain metabolism using hyperpolarized [1–13C]pyruvate and magnetic resonance imaging by Grist, James T., McLean, Mary A., Riemer, Frank, Schulte, Rolf F., Deen, Surrin S., Zaccagna, Fulvio, Woitek, Ramona, Daniels, Charlie J., Kaggie, Joshua D., Matys, Tomasz, Patterson, Ilse, Slough, Rhys, Gill, Andrew B., Chhabra, Anita, Eichenberger, Rose, Laurent, Marie-Christine, Comment, Arnaud, Gillard, Jonathan H., Coles, Alasdair J., Tyler, Damian J., Wilkinson, Ian, Basu, Bristi, Lomas, David J., Graves, Martin J., Brindle, Kevin M., Gallagher, Ferdia A.

“…Hyperpolarized 13C Magnetic Resonance Imaging (13C-MRI) provides a highly sensitive tool to probe tissue metabolism in vivo and has recently been translated…”
Get full text

A phase I trial of the γ-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma by Cook, Natalie, Basu, Bristi, Smith, Donna-Michelle, Gopinathan, Aarthi, Evans, Jeffry, Steward, William P, Palmer, Daniel, Propper, David, Venugopal, Balaji, Hategan, Mirela, Anthoney, D Alan, Hampson, Lisa V, Nebozhyn, Michael, Tuveson, David, Farmer-Hall, Hayley, Turner, Helen, McLeod, Robert, Halford, Sarah, Jodrell, Duncan

“…Background: The Notch pathway is frequently activated in cancer. Pathway inhibition by γ-secretase inhibitors has been shown to be effective in pre-clinical…”
Get full text

Imaging breast cancer using hyperpolarized carbon-13 MRI by Gallagher, Ferdia A., Woitek, Ramona, McLean, Mary A., Gill, Andrew B., Garcia, Raquel Manzano, Provenzano, Elena, Riemer, Frank, Kaggie, Joshua, Chhabra, Anita, Ursprung, Stephan, Grist, James T., Daniels, Charlie J., Zaccagna, Fulvio, Laurent, Marie-Christine, Locke, Matthew, Hilborne, Sarah, Frary, Amy, Torheim, Turid, Boursnell, Chris, Schiller, Amy, Patterson, Ilse, Slough, Rhys, Carmo, Bruno, Kane, Justine, Biggs, Heather, Harrison, Emma, Deen, Surrin S., Patterson, Andrew, Lanz, Titus, Kingsbury, Zoya, Ross, Mark, Basu, Bristi, Baird, Richard, Lomas, David J., Sala, Evis, Wason, James, Rueda, Oscar M., Chin, Suet-Feung, Wilkinson, Ian B., Graves, Martin J., Abraham, Jean E., Gilbert, Fiona J., Caldas, Carlos, Brindle, Kevin M.

“…Our purpose is to investigate the feasibility of imaging tumor metabolism in breast cancer patients using 13C magnetic resonance spectroscopic imaging (MRSI)…”
Get full text